f Unlocking Hope: The Promise of CAR-T Cell Therapy in Cancer Treatment

References

1. JuneC.H. O’ConnorR.S. KawalekarO.U. GhassemiS. MiloneM.C. CAR T cell immunotherapy for human cancer.Science201835963821361136510.1126/science.aar6711 29567707
   [Google Scholar]
2. SadelainM. BrentjensR. RivièreI. The basic principles of chimeric antigen receptor design.Cancer Discov.20133438839810.1158/2159‑8290.CD‑12‑0548 23550147
   [Google Scholar]
3. NeelapuS.S. LockeF.L. BartlettN.L. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.N. Engl. J. Med.2017377262531254410.1056/NEJMoa1707447 29226797
   [Google Scholar]
4. ShahN.N. FryT.J. Mechanisms of resistance to CAR T cell therapy.Nat. Rev. Clin. Oncol.201916637238510.1038/s41571‑019‑0184‑6 30837712
   [Google Scholar]
5. MitraA. BaruaA. HuangL. GangulyS. FengQ. HeB. From bench to bedside: The history and progress of CAR T cell therapy.Front. Immunol.202314118804910.3389/fimmu.2023.1188049 37256141
   [Google Scholar]
6. RafiqS. HackettC.S. BrentjensR.J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nat. Rev. Clin. Oncol.202017314716710.1038/s41571‑019‑0297‑y 31848460
   [Google Scholar]
7. MarofiF. RahmanH.S. Al-ObaidiZ.M.J. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.Stem Cell Res. Ther.202112146510.1186/s13287‑021‑02420‑8 34412685
   [Google Scholar]
8. MarofiF. TahmasebiS. RahmanH.S. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.Stem Cell Res. Ther.202112121
   [Google Scholar]
9. ChakrabortyR. ‘First’ patient free of cancer: Indigenous CAR-T cell therapy brings treatment cost down from Rs 4 crore to Rs 40 lakh.2024Available from: https://indianexpress.com/article/cities/mumbai/indigenous-car-t-cell-therapy-now-available-for-commercial-use-9147148/
   [Google Scholar]
10. PolsonA.G. FujiR.N. The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cell‐surface‐targeted biological agents in patients.Br. J. Pharmacol.201216651600160210.1111/j.1476‑5381.2012.01916.x 22364106
    [Google Scholar]
11. PeplowP.V. Reprogramming T cells as an emerging treatment to slow human age-related decline in health.Front. Med. Technol.20246138464810.3389/fmedt.2024.1384648 38666066
    [Google Scholar]
12. KarstenH. MatrischL. CichutekS. FiedlerW. AlsdorfW. BlockA. Broadening the horizon: Potential applications of CAR-T cells beyond current indications.Front. Immunol.202314128540610.3389/fimmu.2023.1285406 38090582
    [Google Scholar]
13. DagarG. GuptaA. MasoodiT. Harnessing the potential of CAR-T cell therapy: Progress, challenges, and future directions in hematological and solid tumor treatments.J. Transl. Med.202321144910.1186/s12967‑023‑04292‑3 37420216
    [Google Scholar]
14. BonifantC.L. JacksonH.J. BrentjensR.J. CurranK.J. Toxicity and management in CAR T-cell therapy.Mol. Ther. Oncolytics201631601110.1038/mto.2016.11 27626062
    [Google Scholar]
15. CliffE.R.S. KelkarA.H. Russler-GermainD.A. High cost of chimeric antigen receptor T-cells: Challenges and solutions.Am. Soc. Clin. Oncol. Educ. Book20234343e39791210.1200/EDBK_397912 37433102
    [Google Scholar]
16. TahmasebiS. ElahiR. EsmaeilzadehA. Solid tumors challenges and new insights of CAR T cell engineering.Stem Cell Rev. Rep.201915561963610.1007/s12015‑019‑09901‑7 31161552
    [Google Scholar]
17. ElahiR. KhoshE. TahmasebiS. EsmaeilzadehA. Immune cell hacking: Challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells.Front. Immunol.20189171710.3389/fimmu.2018.01717 30108584
    [Google Scholar]
18. SnowdenJ.A. Sánchez-OrtegaI. CorbaciogluS. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2022.Bone Marrow Transplant.20225781217123910.1038/s41409‑022‑01691‑w 35589997
    [Google Scholar]
19. HadilooK. TahmasebiS. EsmaeilzadehA. CAR-NKT cell therapy: A new promising paradigm of cancer immunotherapy.Cancer Cell Int.20232318610.1186/s12935‑023‑02923‑9 37158883
    [Google Scholar]
20. TahmasebiS. ElahiR. KhoshE. EsmaeilzadehA. Programmable and multi-targeted CARs: A new breakthrough in cancer CAR-T cell therapy.Clin. Transl. Oncol.20212361003101910.1007/s12094‑020‑02490‑9 32997278
    [Google Scholar]
21. Al-HaideriM. TondokS.B. SafaS.H. CAR-T cell combination therapy: The next revolution in cancer treatment.Cancer Cell Int.202222136510.1186/s12935‑022‑02778‑6 36419058
    [Google Scholar]